{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:44:36Z","timestamp":1789541076107,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DP1 DA039658"],"award-info":[{"award-number":["DP1 DA039658"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DA032246"],"award-info":[{"award-number":["R01 DA032246"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01 DA045299"],"award-info":[{"award-number":["U01 DA045299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007130","name":"University of Texas System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2021.108568","type":"journal-article","created":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T16:39:43Z","timestamp":1618763983000},"page":"108568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Potentiation of (\u03b14)2(\u03b22)3, but not (\u03b14)3(\u03b22)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7819-3074","authenticated-orcid":false,"given":"Ayman K.","family":"Hamouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malia R.","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois S.","family":"Akinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Alkhlaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asti","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriah","family":"Carper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-0279","authenticated-orcid":false,"given":"Wisam B.","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8502-843X","authenticated-orcid":false,"given":"Yen-Chu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh A.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-2163","authenticated-orcid":false,"given":"Christie D.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Imad","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108568_bib1","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1016\/j.bmcl.2008.08.080","article-title":"Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators","volume":"18","author":"Albrecht","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2021.108568_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pbb.2017.08.013","article-title":"Assessment of nicotine withdrawal-induced changes in sucrose preference in mice","volume":"161","author":"Alkhlaif","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.neuropharm.2021.108568_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.bcp.2015.04.013","article-title":"The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain","volume":"97","author":"Bagdas","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ejp.1092","article-title":"Allosteric modulation of alpha4beta2* nicotinic acetylcholine receptors: desformylflustrabromine potentiates antiallodynic response of nicotine in a mouse model of neuropathic pain","volume":"22","author":"Bagdas","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2021.108568_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1570159X15666170818102108","article-title":"New insights on neuronal nicotinic acetylcholine receptors as targets for pain and inflammation: a focus on alpha7 nAChRs","volume":"16","author":"Bagdas","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bcp.2007.07.011","article-title":"Allosteric modulation of nicotinic acetylcholine receptors","volume":"74","author":"Bertrand","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2017.12.008","article-title":"The wonderland of neuronal nicotinic acetylcholine receptors","volume":"151","author":"Bertrand","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrn2849","article-title":"Nicotine addiction and nicotinic receptors: lessons from genetically modified mice","volume":"11","author":"Changeux","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib8","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1523\/JNEUROSCI.1433-17.2018","article-title":"Altered baseline and nicotine-mediated behavioral and cholinergic profiles in ChAT-cre mouse lines","volume":"38","author":"Chen","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.119.260653","article-title":"The novel CYP2A6 inhibitor, DLCI-1, decreases nicotine self-administration in mice","volume":"372","author":"Chen","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108568_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/jpet.103.054908","article-title":"Characterization of spontaneous and precipitated nicotine withdrawal in the mouse","volume":"307","author":"Damaj","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108568_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41598-018-19790-4","article-title":"LY2087101 and dFBr share transmembrane binding sites in the (alpha4)3(beta2)2 Nicotinic Acetylcholine Receptor","volume":"8","author":"Deba","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2021.108568_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25122923","article-title":"Examining the effects of (alpha 4)3(beta 2)2 nicotinic acetylcholine receptor-selective positive allosteric modulator on acute thermal nociception in rats","volume":"25","author":"Deba","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2021.108568_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/mol.116.106880","article-title":"The (alpha4)3(beta2)2 stoichiometry of the nicotinic acetylcholine receptor predominates in the rat motor cortex","volume":"92","author":"DeDominicis","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib15","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1046\/j.1471-4159.1997.69052216.x","article-title":"Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration","volume":"69","author":"Flores","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108568_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0026-895X(25)08832-7","article-title":"A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment","volume":"41","author":"Flores","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.neuropharm.2011.05.012","article-title":"Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training","volume":"61","author":"Fowler","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuropharm.2013.09.008","article-title":"Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability","volume":"76 Pt B","author":"Fowler","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","article-title":"Neuronal nicotinic receptors: from structure to pathology","volume":"74","author":"Gotti","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bcp.2009.05.024","article-title":"Structural and functional diversity of native brain neuronal nicotinic receptors","volume":"78","author":"Gotti","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1124\/mol.116.103341","article-title":"Photolabeling a nicotinic acetylcholine receptor (nAChR) with an (alpha4)3(beta2)2 nAChR-selective positive allosteric modulator","volume":"89","author":"Hamouda","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/ntr\/ntx183","article-title":"Reversal of nicotine withdrawal signs through positive allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors in male mice","volume":"20","author":"Hamouda","year":"2018","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2021.108568_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.115.098913","article-title":"Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled binding sites in a nicotinic acetylcholine receptor","volume":"88","author":"Hamouda","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib71","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1046\/j.1471-4159.1996.67051953.x","article-title":"Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits","volume":"67","author":"Harvey","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuropharm.2021.108568_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/1873-3468.12884","article-title":"Nicotinic acetylcholine receptors in neuropathic and inflammatory pain","volume":"592","author":"Hone","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2021.108568_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2012.08.012","article-title":"Nicotinic acetylcholine receptors: from basic science to therapeutics","volume":"137","author":"Hurst","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2021.108568_bib72","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.107.132977","article-title":"Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs","volume":"325","author":"Jackson","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2021.108568_bib26","first-page":"76","article-title":"Modulators of nicotinic acetylcholine receptors as analgesics","volume":"5","author":"Jain","year":"2004","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2021.108568_bib27","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1021\/jm040219e","article-title":"Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations","volume":"48","author":"Jensen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108568_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/mol.113.089979","article-title":"The nicotinic alpha5 subunit can replace either an acetylcholine-binding or nonbinding subunit in the alpha4beta2* neuronal nicotinic receptor","volume":"85","author":"Jin","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib29","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity","volume":"274","author":"Kalamida","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2021.108568_bib73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.neuroscience.2004.01.017","article-title":"Rat nicotinic acetylcholine receptor alpha2beta2 channels: comparison of functional properties with alpha4beta2 channels in Xenopus oocytes","volume":"124","author":"Khiroug","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108568_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.118.249359","article-title":"The influence of nicotine on lung tumor growth, cancer chemotherapy, and chemotherapy-induced peripheral neuropathy","volume":"366","author":"Kyte","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108568_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1056-8719(94)00077-H","article-title":"Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model","volume":"34","author":"Langerman","year":"1995","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2021.108568_bib32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bcp.2011.06.044","article-title":"alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain","volume":"82","author":"Lee","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1208\/s12248-009-9090-7","article-title":"Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery","volume":"11","author":"Lester","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2021.108568_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00213-013-3145-2","article-title":"Positive allosteric modulation of alpha 4 beta 2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration","volume":"230","author":"Liu","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib35","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1523\/JNEUROSCI.4731-12.2013","article-title":"Targeted deletion of the mouse alpha2 nicotinic acetylcholine receptor subunit gene (Chrna2) potentiates nicotine-modulated behaviors","volume":"33","author":"Lotfipour","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.neuropharm.2007.05.021","article-title":"Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine","volume":"53","author":"Marks","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/19756","article-title":"Reduced antinociception in mice lacking neuronal nicotinic receptor subunits","volume":"398","author":"Marubio","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108568_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejphar.2016.05.032","article-title":"Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice","volume":"786","author":"Moerke","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnmol.2015.00071","article-title":"Orthosteric and allosteric ligands of nicotinic acetylcholine receptors for smoking cessation","volume":"8","author":"Mohamed","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-013-3207-5","article-title":"Discriminative-stimulus effects of NS9283, a nicotinic alpha4beta2* positive allosteric modulator, in nicotine-discriminating rats","volume":"231","author":"Mohler","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108568_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/mol.106.023044","article-title":"alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine","volume":"70","author":"Moroni","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib42","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1523\/JNEUROSCI.2199-07.2007","article-title":"Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path","volume":"27","author":"Nashmi","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/mol.63.2.332","article-title":"Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors","volume":"63","author":"Nelson","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2013.04.021","article-title":"alpha4beta2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain","volume":"712","author":"Nirogi","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12031-011-9509-3","article-title":"Allosteric modulator Desformylflustrabromine relieves the inhibition of alpha2beta2 and alpha4beta2 nicotinic acetylcholine receptors by beta-amyloid(1-42) peptide","volume":"45","author":"Pandya","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib74","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.neuropharm.2008.03.010","article-title":"Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras","volume":"54","author":"Papke","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/374065a0","article-title":"Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain","volume":"374","author":"Picciotto","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108568_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108568_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2012.03.064","article-title":"Positive allosteric modulation of alpha4beta2 nAChR agonist induced behaviour","volume":"1458","author":"Rode","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108568_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neulet.2004.10.002","article-title":"Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite","volume":"373","author":"Sala","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108568_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1085\/jgp.201010532","article-title":"Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning","volume":"137","author":"Srinivasan","year":"2011","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jmgm.2011.06.008","article-title":"Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures","volume":"30","author":"Taly","year":"2011","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.neuropharm.2021.108568_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrd2927","article-title":"Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system","volume":"8","author":"Taly","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2021.108568_bib53","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1152\/physiolgenomics.00063.2007","article-title":"Nicotine responses in hypersensitive and knockout alpha 4 mice account for tolerance to both hypothermia and locomotor suppression in wild-type mice","volume":"31","author":"Tapper","year":"2007","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.neuropharm.2021.108568_bib54","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1021\/ja3011379","article-title":"Variations in binding among several agonists at two stoichiometries of the neuronal, alpha4beta2 nicotinic receptor","volume":"134","author":"Tavares Xda","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2021.108568_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1476-5381.2012.01989.x","article-title":"Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors","volume":"167","author":"Timmermann","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14622200310001656966","article-title":"Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia","volume":"6","author":"Tritto","year":"2004","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2021.108568_bib57","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1476-5381.2009.00613.x","article-title":"Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects","volume":"159","author":"Ueda","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib58","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bcp.2013.08.001","article-title":"Neuronal nicotinic receptors as analgesic targets: it's a winding road","volume":"86","author":"Umana","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib59","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2174\/1381612822666160201115341","article-title":"Allosteric modulation of nicotinic acetylcholine receptors: the concept and therapeutic trends","volume":"22","author":"Uteshev","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2021.108568_bib60","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1523\/JNEUROSCI.5240-04.2005","article-title":"Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism","volume":"25","author":"Vallejo","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00213-005-0295-x","article-title":"The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice","volume":"184","author":"Walters","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108568_bib62","doi-asserted-by":"crossref","first-page":"9988","DOI":"10.1074\/jbc.M116.771246","article-title":"Unraveling amino acid residues critical for allosteric potentiation of (alpha4)3(beta2)2-type nicotinic acetylcholine receptor responses","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108568_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050944","article-title":"Acute administration of desformylflustrabromine relieves chemically induced pain in CD-1 mice","volume":"24","author":"Weggel","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2021.108568_bib64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1124\/jpet.115.223933","article-title":"Desformylflustrabromine modulates alpha4beta2 neuronal nicotinic acetylcholine receptor high- and low-sensitivity isoforms at allosteric clefts containing the beta2 subunit","volume":"354","author":"Weltzin","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108568_bib65","doi-asserted-by":"crossref","first-page":"108008","DOI":"10.1016\/j.neuropharm.2020.108008","article-title":"Advances in the in vitro and in vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators","volume":"168","author":"Wilkerson","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108568_bib66","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","article-title":"Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations","volume":"82","author":"Williams","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib67","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bcp.2011.05.007","article-title":"Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats","volume":"82","author":"Zhu","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108568_bib68","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1523\/JNEUROSCI.22-20-08785.2002","article-title":"Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum","volume":"22","author":"Zoli","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108568_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2006.03.077","article-title":"5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors","volume":"539","author":"Zwart","year":"2006","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:11:05Z","timestamp":1758438665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":74,"alternative-id":["S0028390821001222"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108568","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiation of (\u03b14)2(\u03b22)3, but not (\u03b14)3(\u03b22)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108568"}}